LeverVenture is an operator-led, mid-market growth equity firm in life sciences and healthcare, the bridge between venture capital and private equity. These pieces cover that passage: deal structures, market conditions, finance and the operating work that carries a company from proof to scale.
The most recent piece leads and every other piece in this category follows it, each with the line that says what it covers. The other categories are one link away.
Growth equity is absorbing a growing share of life sciences and healthcare capital. This market study breaks down the data, the five sectors in play, and where the financing gap actually sits.
By José VasquézEverything else filed under Growth Equity, newest first.
Private equity and venture are converging in the mid-market. What growth companies should borrow from PE — operational value creation, cash discipline, governance — and what they should refuse: control and leverage.
Read this pieceA practical framework for family offices evaluating first-time and early-fund growth equity managers: what to check, what to ignore, and the red flags that matter most.
Read this pieceTerm sheets carry more weight than the valuation headline. This guide walks life sciences and healthcare founders through the economic terms, control terms, and sector-specific issues to watch.
Read this pieceVenture capital is a power-law business, and the end of cheap money exposed a missing rung in the ladder — the Series B/C graduation problem. Why DPI is back, and where the orphaned middle finds capital.
Read this pieceTwo models of growth capital get lumped together as "private equity." This piece separates operator-led from financial-sponsor growth equity and what the difference means for LPs.
Read this pieceThe financial rules change between the seed round and the buyout. A growth equity guide to unit economics, the Rule of 40, capital structure, cash strategy, and the metrics that actually move enterprise value.
Read this pieceDefense-adjacent deep tech is reshaping how founders in life sciences, clean tech, and AI should structure their commercialization and funding strategy. Here's the operator-level view.
Read this pieceHow founders in life sciences, deep tech, and cleantech should evaluate emerging growth equity managers — track record, fund economics, GP skin-in-the-game, and red flags.
Read this pieceA founder-side ranking of the top growth equity firms investing in life sciences — check sizes, deal structures, therapeutic specialization, and how to vet a partner.
Read this pieceA venture repricing shows up in preference stacks and flat rounds before it shows up in a press release. Here is how a reset moves through a cap table.
Read this pieceSecondary markets hit all-time highs in H1 2025 with record transaction volumes The private equity secondary market has exploded.
Read this pieceThe Rule of 40 flattens very different SaaS businesses into one score. Retention composition, cohort payback, margin trend and burn multiple tell them apart.
Read this piecePlatform strategies rarely fail on deal pricing. They fail because integration capacity, not deal flow, is the real constraint on how many acquisitions a platform can absorb.
Read this pieceOperating partners shifted from advisory presence to accountable ownership. The real design question is how compensation and authority are structured, not who is hired.
Read this pieceThe middle market is not buyout in miniature. Less intermediated sourcing, operational rather than financial leverage, and a wider exit set explain why.
Read this pieceA company spanning borders faces five separate underwriting problems: screening, data residency, treaty structure, currency exposure, and enforcement risk.
Read this pieceA carve-out prices at a discount because separation is real work, not margin. Here is what a TSA, stranded costs, and untangled shared IP actually cost a buyer.
Read this piece's comprehensive operational support framework In today's growth equity landscape, capital alone is table stakes.
Read this pieceA founder-level guide to growth equity firms investing in AI healthcare — due diligence frameworks, valuation drivers, reimbursement risk, and exit pathways covered.
Read this pieceThe first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.
Free, no form. The findings, the method and every chart that carries one — complete, not a teaser, and the same text that opens the full report.
Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no list you did not ask to be on.
Disagree with something on this page? That is the most useful message we get.
It reaches a Managing Partner directly, with a copy to the team address. No phone tree, no shared inbox, no marketing sequence.
A partner will reply from a named address.